Prognostic significance of tumour tissue NeuGcGM3 ganglioside expression and predictive value of circulating tumour cell count monitoring in patients receiving racotumomab immunotherapy

Sadeleştirilmiş öğe sayfası
dc.contributor.authorUskent, N.
dc.contributor.authorAyla, S.
dc.contributor.authorMandel, N. Molinas
dc.contributor.authorOzkan, M.
dc.contributor.authorTeomete, M.
dc.contributor.authorBaloglu, H.
dc.contributor.authorAydincer, C.
dc.contributor.authorYergok, H.
dc.contributor.authorDogan, E.
dc.contributor.authorBerk, B.
dc.contributor.authorYazar, A.
dc.date.accessioned2025-10-16T15:22:43Z
dc.date.issued2019
dc.description.abstract44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, SEP 27-OCT 01, 2019
dc.identifier.otherWOS:000491295503312
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/7874
dc.publisherOXFORD UNIV PRESS
dc.sourceANNALS OF ONCOLOGY
dc.titlePrognostic significance of tumour tissue NeuGcGM3 ganglioside expression and predictive value of circulating tumour cell count monitoring in patients receiving racotumomab immunotherapy
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS